New data on rimonabant suggest that the selective endocannabinoid type 1-receptor blocker has beneficial effects on glycemic control and other risk factors in diabetic patients.
In treatment-naive patients with type 2 diabetes, 6 months of rimonabant t…
Sanofi-aventis has withdrawn its application to sell rimonabant, an antiobesity drug. The decision came after a Food and Drug Administration panel recommended that the agency not approve the drug because of concerns that its use could lead to depression and suicidal thinking.
Related Results
Lancet, BMJ studies sound concern over anti-obesity drug rimonabantRimonabant improves cardiovascular risk profileRimonabant improves cardiovascular r…
Rimonabant, an investigational drug that is a cannabinoid-1 receptor blocker, promoted modest but sustained decreases in weight and waist circumference when combined with a low-calorie diet, reported Dr. F. Xavier Pi-Sunyer of the Obesity Research Center at St. Luke’s-Roosevelt Hospital, New …
Mice given the weight-loss drug rimonabant became resistant to alcohol’s fat-building effects in the liver, which suggests the medication may help fight alcoholic fatty liver in humans, says a U.S. study.
Alcoholism is the leading cause of liver disease in Western societies, according to background information in the study.
Rimonabant, which blocks cannabinoid receptors, is approved for weight loss in several European countries but ha…
New findings reported at the American Heart Association Scientific Sessions in New Orleans, Louisiana, show that first-year improvements in cardiovascular risk factors seen in obese patients treated with Sanofi-Aventis’ Acomplia (rimonabant) are sustained in the second year of therapy.
Related Re…
Monster can be defeated only with the help of proper weapon. Obesity is a dangerous monster which is devouring people’s health and their lives. The devil never comes alone; then how can obesity come alone? High blood pressure, high blood sugar, kidney failure, heart attack, arthritis are the killers…
Most Popular
13 Job Interview Mistakes To Avoid
10 Jobs That Pay $30 An Hour
Public Speaking: 7 Secrets Of Great Public Speakers
5 Regular Mistakes In Public Speaking
Employee Incentive Program - Getting The Best Value For Money
> PARIS, France, April 28 /PRNewswire/ — Sanofi-aventis announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Age…
NEW ORLEANS, November 9 /PRNewswire/ —
- Results From Rio-North America Trial Show That First Year Improvements in Cardiovascular Risk Factors Maintained in the Second Year of Treatment
Most Popular
When T Make Job Transfers: Good Reas…
PARIS (AFP) — French pharmaceutical group Sanofi-Aventis said Friday it had withdrawn an application for regulatory approval for its anti-obesity drug Acomplia in the United States.
A panel of experts from the US Food and Drug Administration concluded ear…
June 17, 2004 — A new drug helped obese people drop up to 8.5 pounds over 16 weeks, researchers report.
Its planned brand name — pending FDA approval — is Acomplia. For now, it’s still going by its generic name rimonabant. But it already has a nickname: the munchies drug. That’s because it works like marijuana in reverse. It blocks cannabinoid receptors in the brain.
Rimonabant curbs appetite. It also cuts the urge to s…
